CERO Therapeutics enters new equity line for up to $14.6M from Keystone Capital

CERO THERAPEUTICS HOLDINGS, INC.

Company entered a new Common Stock Purchase Agreement with Keystone Capital for up to $14,591,939 of common stock.
Prior agreements (Feb 2024, Nov 2024, July 2025) raised ~$10.4M total: ~$4.4M (Feb), ~$3.1M (Nov), ~$2.9M (July).
Minimum stock price for purchases set at $0.02; single fixed purchase limited to 10,000 shares or $100,000.
Investor's beneficial ownership capped at 4.99% of outstanding shares; registration rights granted.
Agreement is a continuation of the existing equity line program; no additional commitment shares required.

item 1.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.